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Using proteomic analysis of the nuclear matrix (NM), we found that heterogeneous nuclear ribonucleoprotein K (hnRNP K), a
member of the hnRNP family with pleiotropic functions, was differentially expressed in prostate cancer (PCa) tissues. This study
aimed to characterise the expression of hnRNP K and its subcellular localisation in PCa, utilising immunohistochemical and
quantitative western blot techniques. Furthermore, the hnRNP K expression was studied in human PCa cell lines in order to
determine its modulation by bicalutamide, the anti-androgen widely used in PCa therapy. Immunohistochemical staining of paraffin-
embedded tissues showed that hnRNP K was overexpressed in PCa, where it was localised both in the cytoplasm and in the nucleus.
Staining of non-tumour tissues showed exclusively nuclear localisation and a less intense or absent signal. Immunoblot analysis
demonstrated that the hnRNP K level within the NM was higher in PCa compared with non-tumour tissues and closely correlated
with Gleason score (P¼0.008). Higher expression within the NM was significantly (P¼0.032) associated with poor prognosis. In
two-dimensional western blot analysis hnRNP K presented several isoforms; the one with pI 5.1 was the most differently expressed
between non-tumour and PCa tissues. Preliminary results indicate that hnRNP K can be modulated in vitro by a non-steroidal anti-
androgen. Taken together, our findings suggest that hnRNP K has potential implications at the diagnostic, prognostic and therapeutic
levels in PCa.
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Prostate cancer (PCa) continues to represent a major health
concern. As the introduction of serum prostate-specific antigen
(PSA) into clinical practice in the late 1980s, the incidence of this
tumour has increased whereas the impact on mortality rates is less
clear-cut. PSA has poor specificity and cannot distinguish indolent
tumours from the aggressive ones that need immediate treatment.
New investigation into more accurate diagnostic and prognostic
biomarkers is needed to improve risk stratification and identify
new targets for therapy of PCa (Damber and Aus, 2008).
As the nuclear matrix (NM) is considered to be a good source of
cancer-specific biomarkers (Leman and Getzenberg, 2008), we
utilised a proteomic approach to compare the NM proteins of PCa
with those isolated from non-tumour (NT) tissues. In PCa, we
observed an increase in the complexity of the protein pattern,
which correlated with the level of tumour differentiation (Alberti
et al, 1996, 2000); moreover, a few proteins (called NM-6, 7 and 8)
were significantly correlated with the risk of biochemical progres-
sion (Boccardo et al, 2003). To characterise these potential
biomarkers, protein spots were selected from high-resolution
two-dimensional gels and analysed by mass spectrometry. NM-6
was identified as heterogeneous nuclear ribonucleoprotein K
(hnRNP K) (Barboro et al, 2005).
HnRNP K is a member of the large hnRNP family. It is a
ubiquitous protein present primarily in the nucleus, but it has also
been found in the cytoplasm and mitochondria; it is involved in
the transcription, splicing and translation processes (Bomsztyk
et al, 2004). It is active at the chromatin level, where it is present in
a higher density at transcribed genes with respect to silent ones
(Ostrowski et al, 2003). Moreover, hnRNP K binds directly to the
promoter region of the human c-myc gene (Michelotti et al, 1996)
and promotes neoplastic transformation in an eIF4E-dependent
manner (Lynch et al, 2005). In breast cancer cells, overexpression
of hnRNP K enhances cell proliferation and anchorage-indepen-
dent growth (Mandal et al, 2001), and in several states of enhanced
cell proliferation, increased expression of this protein has also
been found (Ostrowski and Bomsztyk, 2003). Overexpression of
hnRNP K has been shown in many human tumours too, including
lung cancer (Pino et al, 2003), esophageal cancer (Hatakeyama
et al, 2006), oral squamous cell carcinoma (Roychoudhury and
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sChaudhuri, 2007), colorectal cancer (Carpenter et al, 2006b) and
nasopharyngeal carcinoma (Chen et al, 2008). Interestingly, in the
latter three both aberrant hnRNP K localisation and a correlation
between protein expression and patient’s prognosis were also
observed. Until now, very little is known about the behaviour of
hnRNP K in PCa; Nagano et al (2004) demonstrated that the
hnRNP K was strongly overexpressed in PCa with respect to
normal cell lines derived from the same patient and that the
protein was differentially modulated in two cell lines by INF. More
recently, Wang et al (2008) have shown that a novel transcriptional
repressor complex containing Pura and hnRNP K binds the
androgen receptor (AR) gene both in cell lines and in human
prostate tissues. These results prompted us to better characterise
the role of this protein in PCa.
In this study, we have examined the expression of hnRNP K in
both samples from PCa tissues and cultured cell lines. We have
analysed whether the alterations of this protein are correlated with
clinicopathological characteristics and with the follow-up of
patients. In addition, we have studied the sensitivity of hnRNP K
to anti-androgen treatment. Our findings strongly suggest that
hnRNP K is involved in the carcinogenesis process in PCa, is a
potential diagnostic and prognostic marker and could be used to
monitor therapeutic efficiency of anti-androgen agents.
MATERIALS AND METHODS
Patients and tissue samples
Studies were performed on PCa specimens obtained from 49
patients undergoing radical retropubic prostatectomy for clinically
localised PCa between 1996 and 2003. NT tissue was obtained from
contralateral lobe to the cancer zone and four normal human
prostates (NHP) were collected from patients undergoing cystect-
omy for bladder cancer. The project was approved by the local
Ethics Committee. Fresh tissues were immediately frozen in liquid
nitrogen until sample preparation. All tissues were histologically
confirmed by haematoxylin and eosin staining of frozen sections
and only the specimens containing more than 80% of tumour cells
were processed to isolate the NM. The patients’ characteristics are
summarised in Table 1 and the tumours were classified according
to the TNM system. Out of 49 patients included in the present
analysis five patients received postoperative irradiation, five were
treated with adjuvant hormone therapy and one with both
treatments. Patients were followed at regular intervals and PSA
determined. A PSA level of at least 0.4ngml
–1, which was
confirmed by another assay 4 weeks later, was sufficient to
indicate a biochemical progression. After a median follow-up time
of 49.9 months (95% confidence interval (CI) 20.4–80.9), 15
patients were found to have experienced biochemical progression.
Cell culture
LNCaP and PC3 prostate carcinoma cell lines (ATCC, Rockville,
MD, USA) were cultured in RPMI-1640 (Celbio, Milan, Italy)
containing heat-inactivated 10% fetal bovine serum, 1% penicillin,
1% streptomycin and 1% glutamine. LNCaP medium was also
supplemented with 10mM HEPES, 1mM sodium pyruvate and
4.5mg/ml glucose. Cells were cultured in a monolayer in the
presence of 0.1nM 5-a-dihydrosterone for 72h at 371Ci n5 %C O 2,
and subsequently 10mM Bicalutamide (BIC) was added for a
further 72h.
Cell fractionation
The NM was isolated both from tissues and cell lines as already
described (Barboro et al, 1996) with minor modifications. The
nuclear pellet was resuspended in digestion buffer consisting of
10mM NaCl, 3mM MgCl2,1 0 m M Tris-HCl (pH 7.8) (all from
Sigma, St. Louis, MO, USA) and 2mM vanadyl ribonucleoside
complex (New England BioLabs, Beverly, MA, USA), which was
added to prevent the activation of endogenous RNase. Digestion by
1Uml
–1 DNaseI RNase-free (Roche, Mannheim, Germany) was
allowed to proceed for 1h at room temperature. Chromatin
fragments were extracted by addition of (NH4)2SO4 to a final
concentration of 0.25M. The NM was recovered by centrifugation
at 10000g for 15min and extracted again with a large excess
of digestion buffer containing 0.25M (NH4)2SO4. The sample
was again pelleted and solubilised for one- or two-dimensional
(1D- or 2D)-PAGE.
Cytoplasmic and nuclear extracts were prepared from cell
lines exactly as reported by Kim and Tucker (2006). The
nuclear fraction was then suspended in 400ml of 10% SDS, 3%
dithiothreitol, 40mM Tris and 0.1mM EDTA, pH 6.1 and
sonicated for 15s on low power. SDS and dithiothreitol were
added to the cytoplasmic fraction at final concentrations of 10 and
3%, respectively. Solubilisation of the nuclear and cytoplasmic
fractions was carried out for 5min at 1001C. The samples were
delipidated and cleaned as described by Candiano et al (2004).
Protein concentrations were determined using the Bio-Rad
(Mu ¨nchen, Germany) protein microassay with bovine serum
albumin as a standard.
Immunohistochemistry
Immunohistochemistry was carried out using an anti-hnRNP K
antibody (sc-28380, Santa Cruz Biotechnology Inc., Santa Cruz,
CA, USA) diluted 1:800. For each patient, both PCa and NT tissues
were analysed and the more representative tumour sections were
selected. Two different sections (3mm) of the same sample were
treated independently. The sections were deparaffinised and
immunostained using a BenchMark XT automated stainer
(Ventana Medical Systems, SA Strasbourg, France). The antigen-
antibody complex was revealed with the Ventana Medical System/
View DAB (diaminobenzidine) detection system. The sections
were then counterstained with Gill’s haematoxylin and mounted in
Eukitt. An appropriate positive tissue control was used for each
staining run; the negative control consisted of performing the
entire immunohistochemistry procedure on adjacent sections in
the absence of the primary antibody. The sections were observed
with an Olympus light microscope using  10 and  40 objectives.
The extent of immunochemical reactivity in tumour and
Table 1 Patient demographics and tumour characteristics
N¼49 (%)
Median preoperative age, years (range) 64.0 (48.0–77.0)
Median preoperative PSA, ngml
–1 (range) 11.0 (5.0–120.0)
Tumour stage
pT2 24 (49.0)
pT3 24 (49.0)
pT4a 1 (2.0)
Pelvic nodes involved
pN0 26 (53.1)
pN1-2 10 (20.4)
pNx 13 (26.5)
Surgical margins involved 20 (40.8)
Seminal vesicles involved 12 (24.5)
Gleason score
p6 16 (32.7)
¼7 12 (24.5)
47 21 (42.9)
Heterogeneous nuclear ribonucleoprotein K in prostate cancer
P Barboro et al
1609
British Journal of Cancer (2009) 100(10), 1608–1616 & 2009 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
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and graded according to the number of immunoreactive cells and
staining intensity using the scoring system described by Carpenter
et al (2006b).
Gel electrophoresis
1D-PAGE was carried out according to Laemmli (1970). Eight mgo f
protein extracted from different cell fractions (cytoplasm, nucleus
and NM) were loaded onto gels and separated at 5mA/gel for 16h
at a constant temperature of 121C.
High-resolution 2D-PAGE was performed as described earlier
(Barboro et al, 2008). The gels were silver stained (Heukeshoven
and Dernick, 1988) for protein pattern analysis or processed for
western blotting. All of the silver-stained 2D gels were digitised
with a GS-800 densitometer (Bio-Rad) using the same scanning
conditions. Spot detection, gel alignment and normalisation were
performed using the PDQuest software package (Ver. 7.3.0,
Bio-Rad).
Western blot analysis (WB)
Proteins separated by 1D- or 2D-PAGE were transferred to a
Hybond-P membrane (Amersham Biosciences, Piscataway, NJ,
USA) and immunodetection was carried out using the anti-hnRNP
K antibody diluted 1:1200 (Santa Cruz Biotechnology Inc.).
Peroxidase-conjugated anti-mouse (diluted 1:1000) was used as
secondary antibody. As the major components of the NM undergo
appreciable changes during PCa development, it was not possible
to use an internal control to ensure equal loading on the gels.
Therefore, the relative amounts of hnRNP K were determined
following the quantitative method described by Alberti et al
(2000). Briefly, equal quantities (8mg) of the same preparation
were loaded on two 1D-PAGE gels and submitted to electrophor-
esis. One gel was stained with Coomassie brilliant blue R-250 and
densitometric scans were performed in a GS-800 densitometer
(Bio-Rad) and the total amounts of protein (A) were evaluated by
integration of the optical density curve. The second gel was blotted
and immunoreactive bands were detected using Hyperfilm ECL
films (GE Healthcare, Piscataway, NJ, USA), which exhibit a linear
response to light produced from enhanced chemiluminescence.
The relative amounts of hnRNP K were obtained by normalising
the integrated optical density by ECL (B) to the integrated optical
density (A) of the corresponding Coomassie-stained gel. To reduce
differences arising from fluctuations in the experimental condi-
tions of the immunoblot, a fixed (8mg) amount of total protein
extracted from PC3 from the same batch were run on the gels and
the ratio B/A further normalised by the ECL signal of hnRNP K
standard. This method allowed us to obtain quantitative results.
Confocal laser scanning microscopy
LNCaP cells were grown on chamber slides. The slides were
washed two times in PBS, fixed for 15min in 3.7% formaldehyde
and treated for 5min with PBS containing 0.2% Triton X-100. After
15min of blocking in PBS containing 2% BSA, cells were incubated
for 30min in the same buffer with mouse anti-hnRNP K antiserum
(diluted 1:1000; Santa Cruz Biotechnology Inc.). The cells were
then washed three times with PBS before a 30-min incubation with
anti-mouse Alexa Fluor 633-conjugated immunoglobulin (diluted
1:500; Molecular Probes Inc., Eugene, OR, USA). To visualise
nuclei, the cells were incubated with SYTOX Orange nucleic acid
stain (diluted 1:10000; Molecular Probes Inc.) for 10min and
washed in PBS. The cells were then mounted with 80% glycerol in
PBS. Immunofluorescence staining was visualised using an
Olympus FluoView CLSM-FV500 ( 40 and  60 objectives with
an oil-immersion lens).
Statistical analysis
Associations among the principal variables on study, that is,
hnRNP K, age, preoperative PSA, Gleason score, capsular
penetration, surgical margins, seminal vesicles involvement and
pelvic nodes were investigated by using the Pearson correlation
coefficient (Fleiss, 1981). To this aim, variables were categorised as
follows: Gleason score (p7 vs 47), capsular penetration (not vs
yes), surgical margins (not involved vs involved), seminal vesicles
(not involved vs involved), pelvic nodes (not involved vs involved);
hnRNP K, age and PSA were considered as continuous variables.
Biochemical progression-free survival was defined as the time
from surgery to PSA failure (PSA level of 0.4ngml
–1). Curves were
constructed using the Kaplan–Meier method and compared using
the log-rank test. All of the P-values reported are two sided and
Pp0.05 was considered statistically significant (Armitage et al,
2000). The analyses were performed using SPSS version 15.0 for
Windows.
The comparison of the relative amounts of hnRNP K was
performed using t-test within the OriginPro 7.5 software, exporting
the single value of each film.
RESULTS
Expression and subcellular distribution of hnRNP K in PCa
After the identification of the hnRNP K as a potential biomarker by
proteomic analysis (Barboro et al, 2005) in PCa, we have examined
its expression by immunohistochemical (IHC) staining. In NT
tissue, hnRNP K was mostly localised in the nucleus and very low
staining in the cytoplasm was observed; in PCa, the protein was
overexpressed and localised both in the cytoplasm and in the
nucleus (Figure 1A and B). No relationship was seen between
hnRNP K staining and Ki-67 proliferation index (data not shown).
The scores reported in Figure 1C demonstrate that hnRNP K
expression was significantly higher (Po0.0001) in PCa with
respect to NT tissue, both in the cytoplasm and the nucleus.
Besides, more than 80% of the samples of PCa had a high score
(X6) in the nucleus. These results thus confirm the potential
diagnostic value of this protein. No significant correlation was
found between both nuclear and cytoplasmic hnRNP K immuno-
staining and clinicopathological variables; however, the patients
(n¼24) with low total scores (o10) showed a trend towards better
outcomes, which, however, was not statistically significant
(P¼0.085) (Figure 1D).
Expression of hnRNP K associated with the NM in PCa
Based on the hypothesis that the changes in the levels of hnRNP K
would be more significantly associated with the NM rather than the
whole cell, we focused our research on the quantification of hnRNP
K expression within the NM, by 1D immunoblot analysis.
Representative results are reported in Figure 2A, where the
immunoblot patterns of hnRNP K isolated from NHP, NT and
PCa, with different Gleason scores are compared. The use of the
anti-hnRNP K antibody (see Materials and Methods) results in a
highly specific recognition of both hnRNP K and the splicing
variant previously designated hnRNP J (52 and 50kDa, respec-
tively) (Bomsztyk et al, 2004). The relative amounts of hnRNP K
that remain associated with the NM are shown in Figure 2B, where
the tumours were grouped into low-intermediate (Gleason
scorep7) and high-grade (Gleason score47) lesions. HnRNP K
undergoes progressive increase from NHP to NT to PCa; the
differences in expression were significant between NT and PCa
(P¼0.0003), between NT and PCa with low-intermediate Gleason
scores (P¼0.014) and highly significant between low-intermediate
and high Gleason scores (P¼0.008). When we compared the
expression of hnRNP K associated with the NM isolated from PCa
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7–9 the significance disappeared (P¼0.1); however, if we separate
Gleason 7 category group into two groups (3þ4) and (4þ3)
according to primary differentiation pattern and compare the
expression of hnRNP K in PCa with Gleason score 4–7(3þ4) vs
7(4þ3)–9 the difference becomes again statistically significant
(P¼0.017). This indicates that the level of hnRNP K associated
with the NM does not only increase in tumour tissues, but also
depends on the degree of differentiation.
The individual expression values of hnRNP K within the NM in
47 patients have been correlated with clinicopathological variables
(Table 2). The protein expression was strongly correlated with the
involvement of seminal vesicles and, as we have just mentioned,
with the Gleason score. The average expression value of hnRNP K
increased by 3.5 times in PCa (0.60, 95% CI 0.43–0.78) with
respect to NT (0.17, 95% CI 0.08–0.27) (P¼0.002) (Figure 2C).
Using the average value in PCa, which corresponds to the 66.6th
percentile, we have divided the patients into two groups: those
with high expression of hnRNP K (40.60, 16 patients) and those
with low expression (p0.60, 31 patients). As reported in the
Materials and Methods section, after a median follow-up time of
49.9 months (95% CI 20.4–80), 15 patients were found to have
experienced biochemical progression. Patients who showed a good
prognosis expressed low levels of hnRNP K, whereas those who
showed the worst outcome expressed high levels of the protein
(hazard ratio (HR) 2.95, 95% CI 1.05–8.29, P¼0.032) (Figure 2D).
Is there a relationship between the IHC and WB results? To
answer this question, we stratified the patients into four groups,
based on the hnRNP K expression level within the NM (determined
by WB) and in the cell as a whole or in the cytoplasm only
(determined by IHC). Patients whose tumours expressed high
levels of protein both within the NM and in the whole cell showed
the worst outcome. Interestingly, these patients also had high
levels of hnRNP K expression in the cytoplasm (cytoplasm
scoreX4) (Table 3). Therefore, high levels of hnRNP K within
the NM and in the cytoplasm, at the same time, are correlated with
a higher risk of biochemical progression.
Evaluation of hnRNP K phosphorylation state
HnRNP K possesses multiple sites that are inducibly phosphory-
lated; this post-translational modification alters the interaction
between the protein and nucleic acids or other proteins (Ostrowski
et al, 2000). Moreover, cytoplasmic accumulation of hnRNP K is
phosphorylation-dependent (Habelhah et al, 2001). Therefore, we
carried out a preliminary characterisation of the changes in the
phosphorylation state of hnRNP K by combining high-resolution
2D-PAGE with immunoblot analysis. NM proteins isolated from
NT or PCa samples were separated and the gels were either stained
with silver nitrate (Figure 3A and B) or transferred to the
membrane and analysed by WB using the monoclonal antibody
against hnRNP K (Figure 3C and D). Several spots were observed
with molecular weight of 52kDa and pI from 5.1 to 5.3 and with
molecular weight 50kDa and pI from 5.4 to 5.2, corresponding to
hnRNP K and the isoform J, respectively. The global expression of
hnRNP K was significantly higher in PCa compared with NT, and
in particular the most acidic isoforms with molecular weight
52kDa underwent significant increase. The comparison between
auto-radiographic films and 2D maps confirm that the tumour-
specific spot NM-6 corresponds to hnRNP K and it is an acidic
9 8 7 6 5 4 3 2 1
Years
20
40
60
80
P
r
o
g
r
e
s
s
i
o
n
-
f
r
e
e
 
s
u
r
v
i
v
a
l
 
(
%
)
Total score ≥10
Total score <10
Cytoplasmic Nuclear Total
2
4
6
8
10
12
M
e
a
n
 
s
c
o
r
e
NT
PCa Total
Nuclear
Cytoplasmic
NT PCa
7±0.3
5±0.2
2±0.2 4±0.2
6±0.1
10±0.4
AB
CD
Figure 1 Immunohistochemical analysis of hnRNP K expression in PCa. (A, B) Representative images of two PCa samples with different total scores
(9 and 14, respectively); higher magnification of the areas enclosed with lines are reported in the insets. Elevated hnRNP K staining was present both in the
nucleus and cytoplasm of all tumour cells. The dash lines mark the NT areas. The bars correspond to 100mmi n( A) and (B) and 25mm in the insets. (C)
Comparison of the scores of hnRNP K in NT and PCa tissues. The ordinates represent the mean score±s.e. (reported also in the inset); hnRNP K
expression was significantly (Po0.0001) higher in PCa compared with NT tissue both in the cytoplasm and the nucleus. (D) Biochemical (PSA) progression-
free survival according to hnRNP K expression. The dotted curve corresponds to patients (n¼24) whose tumours had a low total score (o10) and the
solid curve those (n¼24) with high total scores (X10); P¼0.085.
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sisoform with pI 5.1. This result explains why in 2D-PAGE the NM-
6 spot was present only in PCa and absent in both NHP and in NT.
On the contrary, in 1D-PAGE and immunohistochemical experi-
ments, even if in minor quantities, hnRNP K was also present in
NHP and NT.
Expression and modulation of hnRNP K in cell lines
The expression profile of NM proteins extracted from PCa tissue
was compared with that of hormone-dependent (LNCaP) and
hormone-independent (PC3) prostate carcinoma cell lines. Repre-
sentative silver-stained gel patterns are reported in Figure 3E and F.
More than 70% of the proteins expressed by the cell lines were
common to PCa; it is interesting to note that six of the eight cancer-
specific proteins, which we have previously found in PCa tissues
(Alberti et al, 2000; Boccardo et al, 2003), were also expressed in the
cell lines. In particular, NM-2, NM-4, NM-5 and NM-6 were
expressed in both cell lines, whereas NM-7 and NM-8 were
expressed only in hormone-insensitive cells. Therefore, these cell
lines are good models to study the role of NM proteins after drug
treatment. It must be pointed out that, in this work, we have studied
only the expression of NM-6, which corresponds to an acidic
isoform of hnRNP K as reported above. Both cell lines were treated
for 72h with 10mM BIC, a non-steroidal anti-androgen currently
used as mono-therapy for locally advanced or biochemically
recurrent PCa. Under these conditions, the maximum inhibitory
effect on cell growth was observed (Boccardo et al,2 0 0 5 ) .
Representative 2D immunoblot experiments are shown in Figure 3.
The protein was expressed both in LNCaP and PC3 cells and several
spots, corresponding to different isoforms, were detectable (Figure
3G and H). After treatment with BIC, the expression of hnRNP K in
LNCaP cells was remarkably decreased whereas PC3 cells were
unaffected (Figure 3I and J). The expression of hnRNP K was also
evaluated in LNCaP cells by confocal microscopy and 1D WB. In
Figure 4A and B, representative optical sections are reported. In
Table 2 Significance of the relationship between the relative amount of
hnRNP K within the NM and patient characteristics
Patient characteristics
Pearson’s correlation
coefficient P-value
Preoperative age 0.102 0.5
Preoperative PSA 0.052 0.7
Capsular penetration  0.087 0.6
Surgical margins involved 0.264 0.07
Seminal vesicles involved 0.330 0.02
Gleason score 47 0.381 0.008
Pelvic nodes involved 0.252 0.08
Table 3 Ability to predict biochemical progression according to hnRNP
K expression in the different cellular compartments
hnRNP K expression n obs
a HR (95% CI) P-value
Within the NM and the whole cell
b
p0.60 and o10 16 2 1.0 0.1
p0.60 and X10 14 6 3.96 (0.79–19.86) 0.1
40.60 and o10 7 3 5.03 (0.83–30.51) 0.08
40.60 and X10 9 4 9.49 (1.61–55.82) 0.013
Within the NM and the cytoplasm
p0.60 and o4 12 2 1.0 0.1
p0.60 and X4 18 6 2.41 (0.48–12.03) 0.3
40.60 and o4 7 3 3.89 (0.64–23.67) 0.1
40.60 and X4 9 4 7.34 (1.25–43.13) 0.025
aobs (observed)¼number of patients with a biochemical progression.
bhnRNP K
expression level was determined within the NM by WB and in whole cell or in
cytoplasm by IHC.
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Figure 2 Expression of hnRNP K associated with NM in PCa. (A)
Representative 1D WB analysis of NM isolated from NHP, NT and PCa
with different Gleason scores. The relative molecular weights of hnRNP K
and the splicing variants J are reported on the left. (B) The comparison
among the relative amounts of hnRNP K as determined by quantitative
analysis of four NHP, 24 NT and 27 PCa samples with Gleason score 4–7
and 20 PCa samples with Gleason score 8–9. The ordinates represent the
mean±s.e. (reported also in the inset). The increase in hnRNP K
expression was found to be significant between NT and PCa with Gleason
score 4–7 (P¼0.014) and highly significant between Gleason score 4–7
and 8–9 (P¼0.008). (C) Scatterplots of relative amounts of hnRNP K
within the NM isolated from NT and PCa samples. Horizontal lines indicate
the mean values. (D) Biochemical (PSA) progression-free survival according
to hnRNP K expression within the NM. The dotted curve denotes patients
(n¼31) whose tumours had low hnRNP K expression (p0.60) and the
solid curve denotes those (n¼16) with high expression (40.60);
P¼0.032.
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suntreated cells, hnRNP K was above all localised in the nucleoplasm;
however, a little fluorescence intensity was also present in the
cytoplasm; moreover, as it is well-known, the protein is preferen-
tially concentrated in the discrete loci referred to as splicing factor
compartments (Dundr and Misteli, 2001). After treatment with BIC,
hnRNP K was absent in the cytoplasm and present in a minor
quantity in the nucleus, where it tended to move towards the
periphery. Quantitation of hnRNP K expression, carried out by 1D
WB, confirmed that the protein was present in all subcellular
compartments (cytoplasm, nucleus and NM) (Figure 4C and D) and
when the cells were exposed to BIC, the expression of hnRNP K
underwent an overall decrease predominantly within the NM (from
2.72±0.49 to 0.75±0.34, P¼0.019).
DISCUSSION
In this study, for the first time, we have provided clear evidence
that hnRNP K is significantly overexpressed in PCa with respect to
NT tissue; moreover, an acidic isoform of this protein is
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Figure 3 Representative 2D gel maps of the NM proteins extracted from NT (A) and PCa (B) tissues and from LNCaP (E) and PC3 (F) cell lines.
Tumour-associated proteins are marked by circles and identified with the same number used in Boccardo et al (2003); silver-stained gels. The proteins
resolved in 2D were transferred to Hybond-P membranes and probed with anti-hnRNP K antibody. Representative 2D WB of NM proteins extracted from
NT (C), PCa (D), LNCaP and PC3 cells in the absence (G and H, respectively) and presence of 10mM BIC for 72h (I and J, respectively). The circles in D,
G, H, I and J highlight the NM-6 spot that corresponds to an acidic isoform of hnRNP K. This isoform is absent in NT (C) and is downexpressed in LNCaP
cells after treatment with BIC (I). The relative molecular weights of standard proteins are reported on the left.
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sexclusively present in tumour cells. Higher expression within the
NM and aberrant cytoplasmic localisation were significantly
associated with poor prognosis. Preliminary results indicate that
hnRNP K is negatively modulated in vitro by the exposure to a
non-steroidal anti-androgen and therefore that it probably occurs
as a result of androgen stimulation.
The correlations between elevated expression of hnRNP K and
tumour development and progression are well documented
(Carpenter et al, 2006a) and the results reported here are in line
with those findings. We have demonstrated that, in PCa, this
increase is more evident within the hnRNP K fraction that is part
of NM. The NM is the protein scaffold that provides the structural
framework for organising chromatin and plays a pivotal role in the
spatial and temporal coordination of gene activation events (Zink
et al, 2004). The hnRNPs are among the most abundant
components of the NM. The interactions of chromatin with the
NM occur by specific DNA sequences called MARs (Matrix
Attachment Regions), which are placed close to the transcription-
ally active regions of chromatin so that transcription is initiated in
regions of chromatin anchored to the NM. We have demonstrated
that several proteins belonging to the hnRNP family bind DNA-
MARs (Barboro et al, 2009) and it is known that hnRNP K binds
both RNA and DNA (Bomsztyk et al, 1997). In addition, our
preliminary experiments (data not shown) indicate that, in the
prostate model, hnRNP K also binds MAR sequences. Therefore,
the increased level of hnRNP K in the NM could be the critical step
towards the activation of the numerous pathways involved in
carcinogenesis, which are potentially regulated by hnRNP K.
HnRNP K could directly or indirectly, through modifications of
protein/protein or RNA complexes, modulate the transition from
an open to a condensed chromatin state. This results in the passage
from a transcriptionally competent to an incompetent state, which
in turn determines the modification of the expression of
several genes. Furthermore, it has been demonstrated that during
differentiation the splicing factor compartments, which contain
hnRNPs, are relocated from internal regions towards the periphery
of the nucleus (Dundr and Misteli, 2001). We observed that, after
treatment with BIC, not only does the expression of hnRNP K
decrease but the protein was invariably found at the nuclear
periphery. The interaction between hnRNP K and nucleic acids
and/or proteins could be regulated by the state of phosphorylation
of the protein.
Cytoplasmic localisation of hnRNP K is phosphorylation-
dependent and is carried out by mitogen-activated protein
kinase/extracellular signal-regulated kinase that phoshorylates the
protein both in vivo and in vitro at Ser
284 and Ser
353 (Bomsztyk
et al, 2004). The phosphorylation may occur primarily in the
nucleus and afterwards the protein may be translocated to
the cytoplasm. Therefore, phosphorylated hnRNP K may modify
the nuclear-shuttling domain and facilitate its cytoplasmic
accumulation (Habelhah et al, 2001). The cytoplasmic accumul-
ation of hnRNP K seems to be an intrinsic feature of transforma-
tion per se, and does not merely reflect the increase in cell
proliferation. In fact Ostrowski and Bomsztyk (2003) reported that
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Figure 4 (A, B) Confocal microscopy analyses carried out on control LNCaP cells clearly show strong hnRNP K staining in the nucleus and lower staining
in the cytoplasm. After exposure to 10mM BIC for 72h, the staining of the cytoplasm disappears and the staining in the nucleus gets fainter. Cells were
immunostained with anti-hnRNP K antibody (green) and DNA was visualised with SYTOX Orange (blue). Images from control (Ctrl) and treated (BIC) cells
were acquired with identical acquisition settings and representative cells were photographed at low magnification (A; scale bars: 25mm) and at high
magnification (B; scale bars: 10mm). (C, D) Comparison between hnRNP K expression, in the different cellular compartments, in control and treated cells.
Representative 1D WB (C); the relative molecular weights are indicated on the left. The ordinates in (D) represent the mean±s.e. (reported also in the
inset) of the relative amounts of hnRNP K, as determined by quantitative analysis, of four BIC treatment experiments and from four to seven different
western blots, as in some samples were run on two different gels. When the cells were exposed to BIC, the expression of hnRNP K underwent an overall
decrease. This decrease was significant within the NM (P¼0.019).
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slevels of nuclear hnRNP K were higher in proliferating hepatocytes
compared with resting cells, but levels of cytoplasmic hnRNP K
were the same or lower in dividing compared with quiescent cells.
An important role has been suggested for cytoplasmic hnRNP K in
nasopharyngeal carcinoma and metastasis, where aberrant cyto-
plasmic localisation of hnRNP K along with overexpression of
thymidine phosphorylase is associated with shorter overall
survival and lower metastasis-free survival (Chen et al, 2008).
Interestingly, in a loss-of-function screening system based on
intracellular expression of single-domain antibodies, Inoue et al
(2007) found that hnRNP K is a potential target for metastasis and
its cytoplasmic accumulation may mediate its role in cell migration
and metastasis. Our findings, namely the overexpression of an
acidic isoform in PCas and the association between the hnRNP K
cytoplasmic accumulation with poor prognosis, are in line with the
above results and further support the possible role for cytoplasmic
hnRNP K in tumour aggressiveness.
We have shown here that after treatment with BIC, the
expression of hnRNP K in LNCaP cells underwent an overall
decrease predominantly within the NM. Additional studies will
determine whether this is a specific effect of the anti-androgen
used here or simply it represents the result of silencing of the gene,
which encodes for this protein under androgen stimulation.
Whatever the mechanism involved, hnRNP K might play a role
in the regulation of AR gene. Wang et al (2008) showed that in
LNCaP cells 50-untranslated region of the AR promoter harbours a
suppressor element, which is directly bound hnRNP and Pura, but
only the regulation of this latter is crucial for the repression of AR
levels. Vice versa Shi et al (2008) have reported that transcriptional
downregulation of AR in the aging rat liver and in oxidatively
stressed hepatoma cells involve hnRNP K through the interactions
with PARP-1 and the first may serve as a stabilising docking
platform for the activating complex that governs AR stimulation;
in this model, silencing of hnRNP K decreased AR expression.
Moreover, we were able to show, utilising the same approach, that
the knockdown of hnRNP K expression gives rise to a loss of the
angiogenic and migratory phenotype of prostate carcinoma cells
(Benelli et al, 2009). Therefore this protein could provide both a
novel therapeutic strategy to control PCa progression and
metastasis and check the answer to hormonal therapy.
Our data, therefore, confirm previous results and support the
hypothesis of Carpenter and Murray (2007) that this protein
probably plays a key role in the carcinogenesis process and could
also be a useful biomarker for disease diagnosis, progression and
prognosis. HnRNP K might also represent a new therapeutic
target. Work is in progress in our laboratory to produce an
antibody specific for acidic isoform present only in PCa, which
might significantly improve upon the sensitivity and specificity
with which PCa is diagnosed and could help to stratify patients
into different prognostic subgroups.
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